Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Zealand Pharma A/S - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Zealand Pharma A/S - Product Pipeline Review - 2014', provides an overview of the Zealand Pharma A/S's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Zealand Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Zealand Pharma A/S including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Zealand Pharma A/S's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Zealand Pharma A/S's pipeline products Reasons to buy - Evaluate Zealand Pharma A/S's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Zealand Pharma A/S in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Zealand Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Zealand Pharma A/S and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zealand Pharma A/S - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Zealand Pharma A/S and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Zealand Pharma A/S Snapshot 5 Zealand Pharma A/S Overview 5 Key Information 5 Key Facts 5 Zealand Pharma A/S - Research and Development Overview 6 Key Therapeutic Areas 6 Zealand Pharma A/S - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Zealand Pharma A/S - Pipeline Products Glance 15 Zealand Pharma A/S - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Zealand Pharma A/S - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Zealand Pharma A/S - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Zealand Pharma A/S - Drug Profiles 19 lixisenatide 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 danegaptide 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ZP-1848 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ZP-2929 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Drug For Cardiovascular Disorders 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Drug For Gastrointestinal Disorders 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Drug For Metabolic Disorders 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Synthetic Peptides for Undisclosed Indications 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ZP-2307 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ZP-2435 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ZP-3022 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ZP-GA-1 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Zealand Pharma A/S - Pipeline Analysis 34 Zealand Pharma A/S - Pipeline Products by Target 34 Zealand Pharma A/S - Pipeline Products by Route of Administration 36 Zealand Pharma A/S - Pipeline Products by Molecule Type 37 Zealand Pharma A/S - Pipeline Products by Mechanism of Action 38 Zealand Pharma A/S - Recent Pipeline Updates 40 Zealand Pharma A/S - Dormant Projects 48 Zealand Pharma A/S - Discontinued Pipeline Products 49 Discontinued Pipeline Product Profiles 49 rotigaptide 49 Zealand Pharma A/S - Locations And Subsidiaries 50 Head Office 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables Zealand Pharma A/S, Key Information 5 Zealand Pharma A/S, Key Facts 5 Zealand Pharma A/S - Pipeline by Indication, 2014 8 Zealand Pharma A/S - Pipeline by Stage of Development, 2014 9 Zealand Pharma A/S - Monotherapy Products in Pipeline, 2014 10 Zealand Pharma A/S - Partnered Products in Pipeline, 2014 11 Zealand Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2014 12 Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2014 13 Zealand Pharma A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Zealand Pharma A/S - Phase III, 2014 15 Zealand Pharma A/S - Phase II, 2014 16 Zealand Pharma A/S - Phase I, 2014 17 Zealand Pharma A/S - Preclinical, 2014 18 Zealand Pharma A/S - Pipeline by Target, 2014 35 Zealand Pharma A/S - Pipeline by Route of Administration, 2014 36 Zealand Pharma A/S - Pipeline by Molecule Type, 2014 37 Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2014 39 Zealand Pharma A/S - Recent Pipeline Updates, 2014 40 Zealand Pharma A/S - Dormant Developmental Projects,2014 48 Zealand Pharma A/S - Discontinued Pipeline Products, 2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
